Prostate Cancer Treatment Expert Dr. David B. Samadi, MD Responds to Cancer Institute of New Jersey Study
March 19, 2010 by Prostate Dr. · Comments Off
Utility And Health-Related Quality Of Life In Prostate Cancer Patients 12 Months After Radical Prostatectomy Or …
UroToday.com – The most common curative treatments for localized prostate cancer (PC), radical prostatectomy (RP) and radiation therapy (RT), have significant effects on quality of life. Most studies measured quality of life using psychometric instruments. Another approach uses the concept of utility. Utility is a global measure, scaled between 0 (dead) and 1 (full…
Alternative Cancer Prostate Treatment
March 17, 2010 by Prostate Dr. · Comments Off
cancer is a disease characterized by the uncontrolled growth, called a tumor, of abnormal cells. Prostate cancer is any type of malignant growth in the prostate. The prostate is one of the male sex glands, located just below the bladder and in front of the rectum. The prostate is about the size of a walnut and it surrounds part of the urethra the prostate makes fluid that becomes part of the semen.…
»»Read more: Alternative Cancer Prostate TreatmentCan Multimedia Lead to More Informed Decisions on Prostate Cancer Treatment?
March 15, 2010 by Prostate Dr. · Comments Off
Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer
Watson Pharmaceuticals, Inc., today announced the U.S. Food and Drug Administration approval of TRELSTAR® 22.5 mg (triptorelin pamoate for injectable suspension), a new twice-yearly formulation of TRELSTAR®, a proven, simple and effective palliative treatment of advanced prostate cancer.
Read more on News-Medical-Net
Can Multimedia Lead to More Informed Decisions on Prostate Cancer Treatment?
Mount Sinai School of Medicine is leading a study…
Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer
March 15, 2010 by Prostate Dr. · Comments Off
Multimedia software program developed to help prostate cancer patients make treatment decisions
Mount Sinai School of Medicine is leading a study of patients newly-diagnosed with prostate cancer to determine if providing them with multimedia materials can help them make more informed treatment decisions. Michael Diefenbach, Ph.D., Associate Professor of Urology at Mount Sinai School of Medicine developed a multimedia software program designed to help prostate cancer patients and their …
Read more…
»»Read more: Watson Pharmaceuticals’ TRELSTAR receives FDA approval for treatment of advanced prostate cancer